{"id":"83c76dd00bc3","type":"article","url":"https://hartvaat.nl/2026/10/01/il-6-remmers-als-nieuwe-aanpak-bij-chronische-nierziekte-en-hart-en-vaatziekten/","title":"IL-6-remmers als nieuwe aanpak bij chronische nierziekte en hart- en vaatziekten","title_en":"Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney international reports","doi":"10.1016/j.ekir.2026.106712","source_url":"https://doi.org/10.1016/j.ekir.2026.106712","authors":["Katherine R Tuttle","David Z Cherney","Roberto Pecoits-Filho","Matteo Pirro","Kevin Yau","Manisha Sahay"],"significance":5,"published":"2026-09-04","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This narrative review examines the role of the interleukin-6 (IL-6) pathway in the shared pathophysiology of chronic kidney disease and cardiovascular disease. It synthesizes current clinical evidence on IL-6 upregulation and evaluates the potential of emerging anti-inflammatory therapies, particularly IL-6 inhibitors, to mitigate cardiorenal risk. While standard treatments often fall short in addressing underlying inflammation, the authors emphasize the need for robust trials to establish the efficacy and long-term safety of targeted immunomodulation. The review offers clinicians a concise overview of a promising therapeutic avenue that remains under active investigation.","created":"2026-08-29T00:56:40Z","updated":"2026-08-29T00:56:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze review belicht de rol van het interleukine-6 (IL-6)-signaalpad bij de gedeelde pathofysiologie van chronische nierziekte en cardiovasculaire aandoeningen. De auteurs vatten de huidige klinische bewijslast samen en bespreken hoe ontstekingsremmende strategieën, waaronder IL-6-remmers in ontwikkeling, de cardiorenale risico’s kunnen verlagen. Hoewel standaardtherapieën vaak tekortschieten in het remmen van inflammatie, benadrukken ze dat grootschalige trials nodig zijn om de effectiviteit en langetermijnveiligheid van gerichte anti-inflammatoire therapieën te bevestigen. Voor cardiologen en internisten biedt het artikel een actueel overzicht van een veelbelovend, maar nog te valideren therapeutisch doelwit.","abstract_original":"Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple shared pathophysiological risk factors and often coexist. Inflammation, particularly mediated by the interleukin-6 (IL-6) pathway, plays an important role in the development and progression of both conditions. In this review, we examine the mechanisms of IL-6 production and signaling and summarize clinical evidence for IL-6 upregulation in CKD and CVD. We discuss the impact of IL-6 on kidney and cardiovascular outcomes, the interplay between CKD, CVD, and associated complications, and the limitations of standard-of-care strategies in attenuating risks related to the presence of inflammation. We also provide an overview of recent advances in anti-inflammatory therapies, including IL-6 inhibitors in development. Finally, we highlight future research directions that are required to establish the efficacy and long-term safety of targeted anti-inflammatory therapies in CKD and CVD."}